Flunitrazolam

FNTZ, Flunazolam

Psychoactive Class

Depressant Anxiolytic GABAergic Sedative

Chemical Class

Flunitrazolam is a novel synthetic depressant of the triazolobenzodiazepine class that first emerged on the research chemical market in 2016.¹ It has no known precedent in the scientific literature prior to its appearance for sale online.² Flunitrazolam is notable for its extreme potency, being active in the low microgram range—a characteristic shared with compounds like flubromazolam and clonazolam. As with all benzodiazepines, it carries significant risk of dependence, and its ultra-potent nature makes accurate dosing particularly critical.

Dosage & Duration

Dosage

Threshold~30 ug

Light40-80 ug

Moderate80-150 ug

Strong150-300 ug

Heavy300+ ug

Duration

Onset20-40 minutes

Peak1-2 hours

Offset2-4 hours

After Effects1-12 hours

Total4-8 hours

Subjective Effects

The experience is dominated by powerful sedation, hypnosis, and anxiety relief, consistent with a highly potent triazolobenzodiazepine active at doses as low as 0.1 mg. Its effect profile is broadly comparable to related compounds such as flunitrazepam, clonazolam, and flubromazolam, with a pronounced hypnotic character that readily progresses into sleep at higher doses. Memory of the period following ingestion is frequently impaired or lost entirely, and blackouts are a recognized risk even at seemingly modest amounts given the compound's microgram-level potency.

Physical

Heavy sedation and pronounced muscle relaxation define the body experience, accompanied by a loss of motor coordination that makes movement clumsy and unsteady.

Sedation

Muscle relaxation

Cognitive

The headspace is one of diminished anxiety and mental quieting rather than stimulation or alteration of perception. Anterograde amnesia is a defining feature, with recall of events after dosing often fragmentary or absent, culminating in full blackouts at higher doses.

Suppressions

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

Flunitrazolam acts as a positive allosteric modulator at the GABA-A receptor benzodiazepine binding site, enhancing the inhibitory effects of gamma-aminobutyric acid (GABA). As a triazolobenzodiazepine, it incorporates a fused triazole ring into the benzodiazepine scaffold, which substantially increases potency compared to its parent compound flunitrazepam, rendering it active in the microgram range. The anticonvulsant properties of benzodiazepines may also involve binding to voltage-dependent sodium channels. Very little direct pharmacological research has been conducted on flunitrazolam specifically, and much of its presumed mechanism is inferred from its structural similarity to other benzodiazepines.

Pharmacokinetics

No specific pharmacokinetic data for flunitrazolam (such as metabolism, enzymes involved, bioavailability, or elimination half-life) is currently available in the published literature.

Metabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AlcoholGHB/GBLOpioidsTramadol

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

DiphenhydraminePCP

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

DXMKetamineMXE

TripSit

Tolerance

Full Tolerance

Tolerance to sedative-hypnotic effects can emerge quickly, often after only a few days of uninterrupted use.

Cross Tolerance

Benzodiazepines (all)

Baseline Reset

Following cessation of use, tolerance generally returns to baseline within 7-14 days. However, individuals with prolonged or intensive use patterns may require significantly longer periods for complete tolerance reset, proportional to the duration and intensity of their usage history.

Harm Potential

Addiction & Dependence

Psychological

High

High abuse potential similar to other potent benzodiazepines.³ Compulsive redosing is commonly reported, and rebound anxiety following use can contribute to cycles of dependence and addiction.⁴

Physical

Extremely High

Extremely physically addictive with potentially life-threatening withdrawal. Abrupt discontinuation after regular use can result in hypertension, seizures, or death.⁵ Gradual tapering over weeks is essential; abrupt cessation is dangerous.⁶

Seizure Risk

Unusually for a benzodiazepine, high to very high doses have reportedly caused seizures without additional triggers such as withdrawal. This proconvulsant effect at high doses is atypical for the drug class. Seizures are also a significant risk during withdrawal from chronic use.⁶

History & Culture

Flunitrazolam is a novel designer benzodiazepine with no documented history prior to its emergence on the online research chemical market. Unlike many benzodiazepines which were first developed by pharmaceutical companies and later diverted to recreational use, flunitrazolam appears to have been…

Legality

By Country

SwitzerlandLegal

Legal as of September 2021. Not a scheduled or controlled substance under Swiss narcotics law.

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Flunitrazolam article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Flunitrazolam

FNTZ, Flunazolam

Flunitrazolam

Contents